Scout by Fusion42
Fusion42 Raise Wire
Money Report
Who RaisedWeekly · Mon 08:30 UTCEarly VelocityWeekly · Thu 08:30 UTCValuation & DilutionBi-weekly · Wed 08:30 UTC
Benchmarks
Benchmarks HomeStartupsRoundsStages
AI Startup IndexCapital FlowAbout

Switch product

Fusion42RaiseScoutWire

Money Report

All editionsWho RaisedWeekly · Mon 08:30 UTCEarly VelocityWeekly · Thu 08:30 UTCValuation & DilutionBi-weekly · Wed 08:30 UTC

Database & benchmarks

Benchmarks HomeStartupsGeographiesRoundsStagesAI Startup IndexCapital Flow Index

Account

Sign in
← Back

Estuary Biotherapeutics

San Francisco, United States

series-a$93M raisedFreshly fundedBiotechDigital HealthDrug Discovery

◆ Total Raised

$93M

◆ Stage

series-a

◆ Location

San Francisco, United States

◆ Team size

1-10

◆ Links

Website ↗

◆ About Estuary Biotherapeutics

Gene therapy company developing kidney-directed AAV delivery platform for autosomal dominant polycystic kidney disease (ADPKD).

◆ What sets it apart

Its AAV delivery platform is designed for local kidney targeting, enabling gene therapies intended to restore polycystin function across the nephron.

◆ Sectors

BiotechDigital HealthDrug Discoveryrare diseasekidney disease

◆ Business

Modeltransactional

CustomerBiopharmaceutical companies, healthcare investors, clinicians, and patients with inherited kidney diseases

◆ Notable

  • Launched with $103 million in committed financing
  • Raised a $93 million Series A led by RA Capital Management
  • Developed two lead ADPKD gene therapy programs, EST-201 and EST-101

◆ Backing funds on Raise

◆ Funding rounds

series-a$93M

16 Oct 2026

Led by RA Capital Management

With Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, National Kidney Foundation Innovation Fund, 4BIO Capital, GV

Source ↗

◆ Explore the market

BiotechDigital HealthDrug DiscoverySeries A

◆ FAQ

What does Estuary Biotherapeutics do?

Gene therapy company developing kidney-directed AAV delivery platform for autosomal dominant polycystic kidney disease (ADPKD).

Where is Estuary Biotherapeutics based?

Estuary Biotherapeutics is based in San Francisco, United States.

How much has Estuary Biotherapeutics raised?

Estuary Biotherapeutics has raised $93M in tracked funding and is currently at the series-a stage.

Who has invested in Estuary Biotherapeutics?

Investors in Estuary Biotherapeutics include RA Capital Management, Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, National Kidney Foundation Innovation Fund, 4BIO Capital and GV.